Nuvation Bio Deal History & Licensing Activity
Nuvation Bio is a life sciences. Over the past three years, Nuvation Bio has been involved in 1 licensing and acquisition transaction, with a primary focus on Small Molecules (2 deals). The company currently has 7 active clinical trials, primarily in Solid Tumors.
Deals (12mo)
1
Active Trials
7
Top Modality
Small Molecules
Focus Area
Solid Tumors
Nuvation Bio Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Nuvation Bio in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| safusidenib | Daiichi Sankyo | Small Molecules | Phase 3 | license | Apr 2026 |
Nuvation Bio Pipeline Focus
Therapeutic areas and modalities where Nuvation Bio is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Nuvation Bio Clinical Pipeline
Nuvation Bio has 7 active clinical trials across 4 development phases.
1
Unknown
1
Phase 1
2
Phase 2
3
Phase 3
See How Your Asset Matches Nuvation Bio's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Solid Tumors assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Neurology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for neurology
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Nuvation Bio Licensing & Deal Activity
Nuvation Bio is a life sciences company that has been actively engaged in licensing transactions across the biopharma landscape. With 1 deal over the past three years, Nuvation Bio ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Nuvation Bio include Solid Tumors (5 deals and trials), Neurology (2 deals and trials), and CNS Disorders (1 deal and trial). In terms of modality, Nuvation Bio has shown particular interest in small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Nuvation Bio and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Nuvation Bio's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.